[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100654090":3},{"organization":4,"outcomesModule":7,"designInfo":29,"detailedDescription":11,"studyPopulation":11,"armGroups":39,"interventions":51,"overallOfficials":11,"centralContacts":11,"locations":61,"responsibleParty":82,"collaborators":11,"id":84,"slug":85,"hasResults":86,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":86,"sex":92,"minAge":93,"maxAge":94,"enrollmentInfo":95,"targetDuration":11,"studyType":98,"phases":99,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":64,"whyStopped":11,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},{"fullName":5,"class":6},"NewAmsterdam Pharma","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Change from Baseline to Week 52 in ptau 217",null,"Baseline, Week 52",[14,17,20,23,26],{"measure":15,"description":16,"timeFrame":12},"Change from Baseline to Week 52 in Alzheimer's disease related biomarker Amyloid β 42\u002FAmyloid β 40 ratio","Measure changes in proteins that can be early signs of Alzheimer's disease.",{"measure":18,"description":19,"timeFrame":12},"Change from Baseline to Week 52 in Alzheimer's disease related biomarker p-tau217\u002FAmyloid β42 ratio","Measure changes in two proteins that can be early signs of Alzheimer's disease.",{"measure":21,"description":22,"timeFrame":12},"Change from Baseline to Week 52 in Alzheimer's disease related biomarker p-tau217\u002FAmyloid β42\u002FAmyloid β40 ratio","Measure changes in three proteins that can be early signs of Alzheimer's disease.",{"measure":24,"description":25,"timeFrame":12},"Change from Baseline to Week 52 in Alzheimer's disease related biomarker BD-tau","Measures a protein released from brain cells that can be early signs of Alzheimer's disease.",{"measure":27,"description":28,"timeFrame":12},"Change From Baseline in Preclinical Alzheimer Cognitive Composite 5 (PACC5) Score","The PACC5 is a standardized set of tests used to measure memory and thinking skills. It is designed to find small changes in memory and thinking that may happen before symptoms of Alzheimer's disease appear. The composite score is derived from standardized scores on five assessments that measure different skills: memory, delayed memory, overall thinking, speed of thinking, and language skills. Higher scores mean better memory and thinking performance.",{"allocation":30,"interventionModel":31,"interventionModelDescription":11,"primaryPurpose":32,"observationalModel":11,"timePerspective":11,"maskingInfo":33},"RANDOMIZED","PARALLEL","PREVENTION",{"masking":34,"maskingDescription":11,"whoMasked":35},"TRIPLE",[36,37,38],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR",[40,45],{"label":41,"type":42,"description":41,"interventionNames":43},"Placebo","PLACEBO_COMPARATOR",[44],"Drug: Matching placebo tablets",{"label":46,"type":47,"description":48,"interventionNames":49},"Obicetrapib","EXPERIMENTAL","10 mg Obicetrapib, once daily",[50],"Drug: Obicetrapib 10 mg",[52,57],{"type":53,"name":54,"description":55,"armGroupLabels":56,"otherNames":11},"DRUG","Obicetrapib 10 mg","once daily 10 mg Obicetrapib tablet",[46],{"type":53,"name":58,"description":59,"armGroupLabels":60,"otherNames":11},"Matching placebo tablets","matching placebo tablet",[41],[62],{"facility":63,"status":64,"city":65,"state":66,"zip":67,"country":68,"countryCode":69,"cosmosGeoPoint":70,"geoPoint":75,"contacts":76},"K2 Medical Research","RECRUITING","Nashville","Tennessee","37204","United States","US",{"type":71,"coordinates":72},"Point",[73,74],-86.78444,36.16589,{"lat":74,"lon":73},[77],{"name":78,"role":79,"phone":80,"phoneExt":11,"email":81},"Victoria Marsh","CONTACT","615-208-K2K2 (5252)","victoria.marsh@k2med.com",{"type":83,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100654090","phase-2-randomized-study-to-evaluate-the-effect-of-obicetrapib-in-participants-with-preclinical-alzheimers-disease-100654090",false,"NCT07794670","Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease","A Phase 2b, Randomized, Double Blind, Placebo Controlled, Parallel Group Trial to Assess the Efficacy and Safety of Obicetrapib in Participants With Preclinical Alzheimer's Disease (SPINOZA Trial)","SPINOZA","Inclusion Criteria:\n\n* participants with preclinical AD\n\nExclusion Criteria:\n\n* APOE genotype not meeting protocol-defined eligibility criteria","ALL","55 Years","85 Years",{"count":96,"type":97},400,"ESTIMATED","INTERVENTIONAL",[100],"PHASE2","A study evaluating Obicetrapib in adults potentially at risk for Preclinical Alzheimer's Disease",[103],"Preclinical Alzheimer's Disease",[105,106,107,108],"Preclinical","Alzheimer's Disease","ptau 217","ApoE","2026-09-23",{"date":111,"type":112},"2026-09-28","ACTUAL",{"date":114,"type":97},"2026-09",{"date":116,"type":97},"2029-05",{"name":5,"class":6},1]